Lupin launches insomnia drug zolpidem in US
The generic version of Intermezzo tablet, the drug is the first product launch from Lupin's GAVIS pipeline with 180 days exclusivity
Lupin Pharmaceuticals Inc, the US-based subsidiary of Lupin Limited, has launched the first product from its GAVIS pipeline, zolpidem sublingual tablets (1.75 mg & 3.5 mg), having received final approval from the US Food & Drug Administration (FDA) earlier, as well as final clearance from the FTC with 180 days of exclusivity.
Zolpidem sublingual tablet is a generic version of Purdue Pharma’s Intermezzo, which had recorded sales of $ 9.46 million in 2015, as per IMS data. Zolpidem sublingual tablet is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
Zolpidem sublingual tablet is a generic version of Purdue Pharma’s Intermezzo, which had recorded sales of $ 9.46 million in 2015, as per IMS data. Zolpidem sublingual tablet is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Apr 05 2016 | 1:18 PM IST